The CARB-X portfolio is the world’s most scientifically diverse, early development pipeline of new antibacterial therapeutics, diagnostics, and prevention. Its mission is to accelerate a diverse portfolio of innovative antibacterial products toward clinical development and regulatory approval. He is also the founding Executive Director and Principal Investigator of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator ( CARB-X), a global non-profit partnership funded by the U.S., U.K., and German governments, Wellcome and the Bill & Melinda Gates Foundation. News & World Report) and leads the Social Innovation on Drug Resistance program.
Fletcher Professor of Law at Boston University, where he co-directs the Health Law Program (ranked #5 in the country by U.S. Kevin Outterson, J.D., LL.M., is Professor of Law and Austin B.
0 kommentar(er)
